{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059031","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.898934+00:00","generated_at":"2026-06-02T07:05:51.776273+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zura Bio Q1 net loss $7.7M; cash $89.8M, closes $112.5M placement, appoints CEO","bullets":["Net loss $7.7M vs $9.6M prior year; cash $89.8M at March 31, 2024.","Closed oversubscribed $112.5M private placement in April 2024 from institutional investors.","Appointed Robert Lisicki as CEO and Kiran Nistala as CMO.","On track for Phase 2 trials: tibulizumab in SSc Q4 2024, HS Q2 2025.","Cash runway extended through 2027 with placement factored in."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059031","json":"https://secwatch.observer/filing/0001104659-24-059031.json","markdown":"https://secwatch.observer/filing/0001104659-24-059031.md","text":"https://secwatch.observer/filing/0001104659-24-059031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/0001104659-24-059031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/tm2413941d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:05:51.776273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4149cdf05d1640c3326b85e864e2b25ac04ccd5c","claim":"Zura Bio Ltd reported first quarter 2024 results: net income $7.7 million.","evidence_excerpt":"Net loss for the first quarter of 2024 was $7.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/0001104659-24-059031-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"$7.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}